Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced that it has received approval from Amazon e-commerce platform to sell Tollovid® and Tollovid Daily™, the Company’s 3CL protease (MPro) inhibiting dietary supplements to support health immune function.
Amazon.com is an international e-commerce company that offers online retail shopping services. It is the largest e-retailer in the United States with $385 billion in annual sales in 2020. In response to the increasing demand for immune support products, Todos Medical launched Tollovid and Tollovid Daily™ initially via the Company’s www.mytollovid.com website. Todos expects to target upcoming family gatherings like Thanksgiving and Christmas where close contact makes it increasingly more important to inhibit 3CL protease in order to help support the immune system. Both Tollovid and Tollovid Daily have 60 caplets per bottle. Tollovid Daily was designed for a twice daily dosing schedule for the person on the go seeking daily immune support. Tollovid was designed for a 12 pills per day, 5-day dosing schedule when a person is seeking maximum immune support over that period.
“Having Tollovid and Tollovid Daily available on Amazon is a great outlet to expand the reach of our brand,” said Gerald Commission, CEO of Todos Medical. “Amazon is one of the largest, most well-known e-commerce platforms in the world giving our Tollovid products a greater level of notoriety, making them much easier to find and purchase with confidence. Along with our recent ability to accept cryptocurrencies through Coinbase Commerce at www.MyTollovid.com, we believe Amazon will further widen our appeal and help us capture significant market share in the dietary supplement market. We are confident that our Tollivid products will be a hit with consumers who understand the importance of 3CL protease inhibition to support immune function, especially heading into the close contact times of this end of year holiday season with Thanksgiving, Hanukkah, Christmas, other religious holidays and New Year’s Eve coming in the months ahead with immune health risks having increased dramatically. Our dietary supplement uses all natural ingredients, is vegan-friendly and has no known harmful side effects even at high dose levels. As the pharmaceutical industry has started to focus on 3CL science and its potential immune health benefits, Todos is positioned to capitalize with Tollovid products available on the market now, allowing breakthroughs in this important research area to help accelerate demand.”
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. In 20201, Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is focused on the commercialization of Videssa and will bring the TBIA tests to market thereafter.
Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic. The Joint-Venture is pursuing the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. The Company’s proprietary therapeutic candidate Tollovir™ is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to initiate Phase 2/3 clinical trials for both hospitalized and non-hospitalized patients in Israel.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States. The products cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.
For more information, please visit https://www.todosmedical.com/.